Results 31 to 40 of about 9,770,551 (325)

Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)

Alzheimer's & Dementia, 2021
The estimate of people with clinical Alzheimer's disease (AD) and mild cognitive impairment provides an understanding of the disease burden.
K. Rajan, J. Weuve, L. Barnes, Elizabeth A Mcaninch, R. Wilson, Denis A. Evans   +5 more
semanticscholar   +1 more source

Association of Heel Bone Mineral Density With Incident Disability and Mortality in Community‐Dwelling Older Adults

JBMR Plus, 2020
Age‐related bone loss is common in older adults. However, the association of low bone mass with incident disability and mortality is not well established.
Ryan D Ross, Raj C Shah, Sue E Leurgans, Aron S Buchman, David A Bennett   +4 more
doaj   +1 more source

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer\u27s disease [PDF]

, 2019
Interest in understanding the roles of white matter (WM) inflammation and damage in the pathophysiology of Alzheimer disease (AD) has been growing significantly in recent years.
Ances, Beau M, Benzinger, Tammie L.S., Blazey, Tyler, Cairns, Nigel J, Chen, Charlie, Cruchaga, Carlos, Fagan, Anne M, Gordon, Brian A, Liu, Jingxia, Morris, John C, Shimony, Joshua S, Su, Yi, Sutphen, Courtney L, Wang, Qing, Wang, Yong   +14 more
core   +2 more sources

Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment

NeuroImage: Clinical, 2019
NIA-AA diagnostic criteria include volumetric or visual rating measures of hippocampal atrophy (HA) as a diagnostic biomarker of Alzheimer's disease (AD).
Neus Falgàs, Raquel Sánchez-Valle, Núria Bargalló, Mircea Balasa, Guadalupe Fernández-Villullas, Beatriz Bosch, Jaume Olives, Adrià Tort-Merino, Anna Antonell, Cristina Muñoz-García, María León, Oriol Grau, Magdalena Castellví, Nina Coll-Padrós, Lorena Rami, Alberto Redolfi, Albert Lladó   +16 more
doaj   +1 more source

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. [PDF]

, 2019
Systems biology studies have demonstrated that different (epi)genetic and pathophysiological alterations may be mapped onto a single tumor's clinical phenotype thereby revealing commonalities shared by cancers with divergent phenotypes.
Goetzl, Edward J, Hampel, Harald, Kapogiannis, Dimitrios, Lista, Simone, Vergallo, Andrea   +4 more
core   +2 more sources

Improved Cardiorespiratory Fitness Is Associated with Increased Cortical Thickness in Mild Cognitive Impairment [PDF]

, 2015
Cortical atrophy is a biomarker of Alzheimer’s disease (AD) that correlates with clinical symptoms. This study examined changes in cortical thickness from before to after an exercise intervention in mild cognitive impairment (MCI) and healthy elders ...
Alfini, Alfonso J., Nielson, Kristy A., Reiter, Katherine, Smith, J. C., Smith, Theresa J., Weiss, Lauren R.   +5 more
core   +2 more sources

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Alzheimer's & Dementia
The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD).
Clifford R Jack, J. S. Andrews, Thomas G. Beach, Teresa Buracchio, B. Dunn, Ana Graf, Oskar Hansson, Carole Ho, William Jagust, E. McDade, J. Molinuevo, O. Okonkwo, Luca Pani, M. Rafii, P. Scheltens, Eric R. Siemers, H. Snyder, R. Sperling, C. Teunissen, Maria C. Carrillo   +19 more
semanticscholar   +1 more source

Forecasting the progression of Alzheimer's disease using neural networks and a novel preprocessing algorithm

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Introduction There is a 99.6% failure rate of clinical trials for drugs to treat Alzheimer's disease, likely because Alzheimer's disease (AD) patients cannot be easily identified at early stages. This study investigated machine learning approaches to use
Jack Albright, Alzheimer's Disease Neuroimaging Initiative   +1 more
doaj   +1 more source

Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease. [PDF]

, 2018
Autosomal dominant Alzheimer's disease (ADAD) is a small subset of Alzheimer's disease that is genetically determined with 100% penetrance. It provides a valuable window into studying the course of pathologic processes that leads to dementia.
Coppola, Giovanni, Huang, Sung-Cheng, Jann, Kay, Liu, Collin Y, Mack, Wendy J, Ringman, John M, Wang, Danny JJ, Wong, Koon-Pong, Yan, Lirong   +8 more
core   +3 more sources

Comprehensive Review on Alzheimer’s Disease: Causes and Treatment

Molecules, 2020
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities.
Zeinab Breijyeh, R. Karaman
semanticscholar   +1 more source